Group 1 - The conference focused on supporting the high-quality development of strategic emerging industries and future industries in Beijing, with the establishment of specialized committees for artificial intelligence, healthcare, embodied intelligence, and new energy materials [1][2] - The Vice Chairman of the All-China Federation of Industry and Commerce emphasized the importance of integrating technological and industrial innovation, and creating a collaborative system to support the high-quality development of the private economy in Beijing [1] - The Chairman of Beijing Municipal Political Consultative Conference highlighted the need to leverage the resources of the Federation to promote the coordinated development of industrial chains and financial systems, and to enhance innovation-driven mechanisms [1][2] Group 2 - The Beijing Federation of Industry and Commerce aims to implement four major projects: ideological guidance, mutual promotion, problem-solving for enterprises, and empowerment to enhance the integration of emerging and future industries [2] - The Federation will actively seek funding, projects, talent, and support for activities to create a collaborative effort in supporting services for industries [2]

Core Viewpoint - The initiative to bring traditional Chinese medicine (TCM) into universities aims to address students' health issues and promote wellness through innovative outreach methods [2][4]. Group 1: TCM Outreach and Engagement - TCM experts are visiting multiple universities in Shanghai to provide free consultations and health advice to students and faculty [1][2]. - The initiative includes a mobile TCM cultural promotion vehicle that offers herbal teas and educates students about TCM principles [1][4]. - The approach is designed to resonate with younger audiences, moving away from traditional didactic methods to more engaging formats [2]. Group 2: Health Issues Addressed - Common health concerns among students include anxiety, sleep problems, and menstrual discomfort, often exacerbated by stress and lifestyle choices [2][3]. - TCM practitioners are teaching students techniques to alleviate these issues, such as acupressure for eye strain and dietary recommendations for menstrual health [3][4]. - The emphasis is on developing healthy habits early in life to prevent future health problems [3]. Group 3: Student Reception and Feedback - Students have shown a strong interest in TCM, with many expressing a desire to learn more about its benefits and practices [3][4]. - Positive testimonials highlight the effectiveness of TCM treatments, such as acupuncture for pain relief and herbal remedies for skin conditions [3][4]. - The mobile TCM promotion vehicle has garnered significant attention, indicating a high level of engagement from the student body [4].

Group 1 - The market is witnessing a rapid increase in new fund issuance, with several funds ending their fundraising periods early to seize investment opportunities [1][2] - On June 12, multiple equity funds announced early closure of their fundraising, indicating strong demand and optimism among fund companies [1] - The first batch of new floating management fee funds has already exceeded 8 billion yuan in issuance scale, reflecting a shift in fund management strategies [1] Group 2 - New funds are being established quickly, with some having fundraising periods as short as 2 days, highlighting a focus on swift market entry [2] - Fund managers are actively purchasing their own funds, demonstrating confidence in the market's long-term stability and growth potential [2] - Economic resilience and potential in China are expected to support market valuation recovery, with sectors like AI, high-end manufacturing, and biomedicine showing promising developments [3]

以下文章来源于21新健康 ，作者李佳英 21新健康 . 21世纪传媒 · 公众号矩阵成员。 编 辑丨季媛媛 图 源丨图虫 原料药领域又现垄断案。 近日，联环药业称收到天津市场监管委员会的《行政处罚决定书》， 因操纵地塞米松磷酸钠 原料药价格，被罚没6103.82万元，占其2024年净利润的72.53% 。而就在近期，津药药业、 仙琚制药也因同一垄断行为被重罚， 三家企业罚没总额高达3.26亿元 。 涉事药企表示将立即组织整改，终止相关不当行为，并积极主动向客户寄送《调价通知函》 。 这场风暴涉及的地塞米松，曾被列入《新型冠状病毒感染的肺炎诊疗方案》。然而，根据公开 信息， 其价格曾从0.35元/支暴涨至98.76元/支，涨幅高达282倍 。 相 关 处 罚 决 定 书 披 露 了 背 后 的 垄 断 手 法 ： 多 家 药 企 及 相 关 人 员 不 仅 达 成 " 停 止 价 格竞争、共同涨价"的口头协议，还通过商业公司"兜底采购"确保垄断实施。 "津药药业、联环药业、西安国康瑞金和仙琚制药这四家企业的行为属于典型的串通涨价。"北 京市京都律师事务所反垄断部主管合伙人、耀时跨境合规研究院研究员金毅向21世纪 ...

Group 1 - The event "China-Africa Traditional Medicine Trade Cooperation" was held in Changsha, focusing on building a new ecosystem for collaborative development in traditional medicine between China and Africa [1] - Traditional Chinese medicine (TCM) has been shared with 196 countries and regions, gaining acceptance for its unique advantages in disease prevention, treatment, and rehabilitation [1] - China has signed memorandums of understanding for traditional medicine cooperation with 10 countries, including Algeria and Ghana, and established TCM centers in Zimbabwe, Comoros, Morocco, and Mauritius [1] Group 2 - The Chinese government emphasizes the importance of traditional medicine cooperation with Africa, integrating it into the agenda of the 2024 China-Africa Cooperation Forum [1] - The event is a significant step in implementing the outcomes of the China-Africa Cooperation Forum, aimed at enhancing traditional medicine collaboration [1] - Zimbabwe's Minister of Health expressed the desire to collaborate with Chinese enterprises and research institutions to improve the production capacity of traditional medicine in Zimbabwe [2]

证券代码：301246 证券简称：宏源药业 答：您好，公司固态硫化物电解质已完成公斤级实验，正处 于工艺优化的开发阶段，没有量产供货。感谢您的关注！ 5、董秘，请问公司在固态电池方面，有何布局，目前进展如何？ 答：您好，公司固态硫化物电解质已完成公斤级实验，正处 于工艺优化的开发阶段，后续的相关进展或变化，公司将严格按 照相关规定及时履行披露义务。 感谢您的关注！ 湖北省宏源药业科技股份有限公司 投资者关系活动记录表 编号：2025-002 | | | □特定对象调研□分析师会议 | | --- | --- | --- | | 投资者关系活动 | □媒体采访□业绩说明会 | | | 类别 | □新闻发布会□路演活动 | | | | □现场参观 | | | | 年湖北辖区上市公司投资者网上集体接待日活动）  其他（2025 | | | 参与单位名称及 | 线上参与"2025 年湖北辖区上市公司投资者网上集体接待日活 | | | 人员姓名 | 动"的全体投资者 | | | 时间 | 2025 年 6 月 12 日 (周四) 下午 14:30~16:50 | | | 地点 | 全景网"投资者关系互动平台"（htt ...

主题一 医药板块经过4年调整，疫情受益高基数、医保局控费超预期、医疗反腐冲击等负面预期 逐步消化，机构相对低配。与此同时，中国医药产业经过持续创新转型，在全球市场的认 可度和影响力快速提升。 公司2024率先启动学术营销模式转型，推进"潘医生工程"，虽然短期内面临转型压力， 但增强了核心产品的放量潜力。 公司深化精细化分层分线销售，根据产品特性和治疗领域差异划分销售线，对金振口服 液、杏贝止咳颗粒等品种实施专人专做；逐步强化OTC布局，提升终端覆盖率，实现多业 态并举，20 2 4年公司销售费用支出15.35亿元，同比下降20. 7%。 此外，公司研发管线价值得到体现， 2024年收购中新医药完善生物药领域的研发布局， 自身在中药、化学药和生物药领域也有多个品种陆续进入临床或者获批上市阶段。 梁 广 楷 预 计 20 2 5 - 2027 年 将 实 现 归 母 净 利 润 4.4/ 5.3/ 6.3 亿 元 ， 同 比 增 长 1 3 .0%20.2%/ 1 8 . 4%，对应PE为21/ 17/ 15倍。 该公司是 ...

Core Viewpoints - The Chinese medicine industry is expected to see a performance turning point, with significant improvements in revenue and profit growth anticipated in Q2 2025 compared to Q1 2025, and continued growth in H2 2025 [3][7] - The industry exhibits characteristics similar to the banking sector, including high cash reserves, substantial dividends, and low profit volatility, with minimal impact from overseas situations [3][7] Key Indicators Tracking - Influenza data has stabilized, reducing revenue growth pressure on companies [11] - The price index of Chinese medicinal materials has declined, which is expected to alleviate gross margin pressure [13] - Institutional holdings are low, with the proportion of fund holdings in the Chinese medicine sector dropping to 0.46% as of Q1 2025, indicating potential for increased investment interest under favorable tariff policies in the U.S. [18] - The sector's valuation is slightly above the average level since 2021, with a TTM price-to-earnings ratio of 27.78x as of June 12, 2025 [21] Investment Recommendations - Companies with stable and rapid profit growth and new consumption logic include Dong'e Ejiao and Lingrui Pharmaceutical, with a focus on Mayinglong [30] - High-barrier, large-cap state-owned enterprises with light institutional positions include Tianshili, Yunnan Baiyao, Tongrentang, and Pianzaihuang [30][6] Mid-Year Performance Outlook - The report provides a forecast for the first half of 2025, indicating expected year-on-year growth rates for various companies, with Dong'e Ejiao projected to grow by approximately 20% in Q2 2025 [34]

6月1 2日下午，为深入贯彻落实习近平总书记在民营企业座谈会上的重要讲话精神和党中央关 于"因地制宜发展新质生产力、加快建设现代化产业体系"的决策部署，根据北京市壮大战略性 新兴产业、培育未来产业的工作要求，北京市工商联举办支持服务首都战略性新兴产业和未来 产业高质量发展大会。全国工商联副主席安立佳，北京市政协副主席、市工商联主席燕瑛等领 导出席大会并发表讲话，北京市委统战部副部长、市工商联党组书记严卫群主持会议。 图为全国工商联副主席安立佳 图为北京市政协副主席、市工商联主席燕 瑛 会上，北京市工商联通报支持服务首都战略性新兴产业和未来产业工作情况，宣布关于成立 4+1专委会（人工智能、医药健康、具身智能、新能源新材料四个产业专委会和投融资专委 会）的决定，任命主任、副主任，并为主任、副主任颁牌。 图 为 北京市委统战部副部长、市工商联党组书记 严 卫 群 | 主任 | | 北京市工商联投融资 | | | --- | --- | --- | --- | | 张膏糕 | 北京市工商业联合会党组成员、副主席 | 解 骑 唐劲草 | 中国民生银行北京分行行长助理 | | 副主任 | | 邓艳芳 | 北京清控水木投 ...

Market Overview - The Hong Kong stock market experienced a collective decline on June 12, with the Hang Seng Index falling by 1.36%, the Hang Seng China Enterprises Index down by 1.53%, and the Hang Seng Tech Index decreasing by 2.2% [1] - Various sectors, including short video, cloud computing, and tech stocks, saw significant drops, with Kuaishou-W down 5.87% and Alibaba-W down 3.21% [1] Sector Performance - The consumer sector faced pressure, with notable declines in beer, sports goods, and airline stocks. Budweiser APAC dropped 6.39%, while Meituan-W fell by 1.95% [1] - The automotive industry, including lithium batteries and smart driving concepts, also saw a downturn, with China Graphite down 12.36% and Xpeng Motors-W down 6.66% [2] - Chip and robotics stocks experienced declines, with Horizon Robotics-W down 3.9% and SMIC down 2.04% [2] Gainers - Pharmaceutical stocks showed resilience, with China Biologic Products rising by 19.29% due to anticipated significant business developments [3] - Other biopharmaceutical companies like Junshi Biosciences and Zai Lab also saw substantial gains, with increases of 12.35% and 8.65% respectively [3] Gold and Precious Metals - Gold and precious metals stocks rose, driven by global gold purchasing trends and rising gold prices. Zijin Mining increased by 4.93% [4] - The global demand for gold as a reserve asset has surged, with central banks increasing their gold holdings amid geopolitical tensions [4] Notable Stocks - Cloudfin Financial, associated with Ant Group, surged by 54.24% following reports of plans to apply for stablecoin licenses in Singapore and Hong Kong [4] - Jiuyuan Gene saw a remarkable increase of 43.73%, marking its fourth consecutive day of gains [5]